<DOC>
	<DOCNO>NCT02409381</DOCNO>
	<brief_summary>Prospective , multicenter , phase IV , open , randomize , parallel , control , 288 ( two hundred eighty-eight ) participant sex , age 40 75 year randomly allocate one two treatment group , treatment group 01 dry extract Curcuma longa complexed phosphatidylcholine ( Motore® ) , treatment group 02 ibuprofen ( Alivium® ) .</brief_summary>
	<brief_title>Extract Curcuma Longa Complexed With Phosphatidilcholine ( Motore® ) Treatment Adults With Knee Osteoarthritis</brief_title>
	<detailed_description>This study evaluate efficacy safety Dry Extract Curcuma Longa complexed phosphatidilcholine ( Motore® ) Compared Ibuprofen ( Alivium® ) treatment adult knee osteoarthritis . The study population consist participant sex , age 40 80 year old clinical diagnosis knee osteoarthritis ( tibiofemoral joint ) base clinical radiological criterion ( Grades 2 3 Kellgren Lawrence ) osteoarthritis symptom last six ( 06 ) month precede start study . They randomly allocate one two treatment group , treatment group 01 dry extract Curcuma longa complexed phosphatidylcholine ( Motore® ) , treatment group 02 ibuprofen ( Alivium® ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Participants sex ; Age great equal 40 year less equal 75 year ; Clinical diagnosis osteoarthritis knee ( tibiofemoral joint ) base clinical radiological criterion ( Grade 2 3 Kellgren Lawrence ) specify : Pain movement affect knee day last month , least partial relief rest ; Presence osteophytes least 1 mm radiological imaging , report issue qualified professional center ; Symptoms osteoarthritis last 06 month precede start study ; Visual Analogue Scale 40mm great value ( consider data obtain randomization visit ) ; Ability understand consent participate clinical study , manifest signing Informed Consent Form ( ICF ) . Any find clinical observation ( clinical physical examination ) laboratory find interpret researcher medical risk participation clinical trial ; Any find ECG examination investigator physician considers risk research participant participation clinical trial ; Known hypersensitivity component medication use study ; Women pregnancy nursing period ; premenopausal woman agree use acceptable contraceptive method ( oral contraceptive , injectable contraceptive , hormonal implant , barrier method , abstinence , hormonal patch tubal ligation ) ; except surgically sterile ( bilateral oophorectomy hysterectomy ) ; concomitant arthropathy may confuse interfere pain assessment efficacy , include : inflammatory arthropathy ( rheumatoid arthritis , systemic lupus erythematosus , spondyloarthropathy , psoriatic arthritis , polymyalgia rheumatic ) , gouty arthritis , acute episode monoarthritis compatible pseudogout , Paget 's disease involvement joint study , history septic arthritis , avascular necrosis intraarticular joint study , Wilson 's disease , hemochromatosis , alkaptonuria , primary osteochondromatosis fracture ; Infectious Arthritis gonococcal syphilitic ; History significant collateral ligament injury , anterior cruciate , meniscus joint study , require surgery immobilization three week ( minor ligament injury , six month prior study , exclusion criterion ) ; History arthroscopy affect knee six month precede entry research participant study ; History illness , opinion investigator , might confound result study research participant put additional risk ; Treatment corticosteroid follow : Use corticosteroid orally intramuscularly one month prior randomization visit ( V0 ) ; Administration intraarticular corticosteroid , joint study previous three month randomization visit ( V0 ) ; Administration intraarticular corticosteroid joint visit prior randomization ( V0 ) month ; intraarticular injection hyaluronic acid joint congener study last twelve month prior randomization visit ( V0 ) ; Implementation medical treatment osteoarthritis prerandomization visit ( V0 ) month ; Body Mass Index ( BMI ) equal great 35 ; Participant use Prohibited Drug ; presence serious psychiatric illness kind prevents proper performance studyrelated procedure good adherence treatment ; Participant relation second degree kinship relationship employee employee Sponsor Research Center .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>